Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine-Reference-Cited by-同舟云学术

Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine

Published:2022-05-19 Issue:20 Volume:386 Page:1910-1921
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Moreira Edson D.¹,Kitchin Nicholas¹,Xu Xia¹,Dychter Samuel S.¹,Lockhart Stephen¹,Gurtman Alejandra¹^ORCID,Perez John L.¹,Zerbini Cristiano¹,Dever Michael E.¹,Jennings Timothy W.¹,Brandon Donald M.¹,Cannon Kevin D.¹,Koren Michael J.¹,Denham Douglas S.¹,Berhe Mezgebe¹,Fitz-Patrick David¹,Hammitt Laura L.¹,Klein Nicola P.¹,Nell Haylene¹,Keep Georgina¹,Wang Xingbin¹,Koury Kenneth¹,Swanson Kena A.¹^ORCID,Cooper David¹,Lu Claire¹,Türeci Özlem¹,Lagkadinou Eleni¹,Tresnan Dina B.¹,Dormitzer Philip R.¹,Şahin Uğur¹,Gruber William C.¹,Jansen Kathrin U.¹

Affiliation:

1. From Associação Obras Sociais Irmã Dulce and the Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., G.K.); Vaccine Research and Development, Pfizer, Collegeville, PA (X.X., J.L.P., X.W.); Vaccine Research and Development, Pfizer (S.S.D.), and California Research Foundation (D.M.B.), San Diego, and Kaiser Permanente Vaccine Study Center, Oakland (N.P.K.) — all...

Funder

Pfizer

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2200674

Reference21 articles.

1. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

2. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

3. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents